Anne Worsaae
Anne Worsaae has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Amedee Des Georges
Department of Molecular Pathobiology, College of Dentistry, New York University, New York, USA
21 shared publications - Camilla Fröhlich
Servier Symphogen A/S 1 , Ballerup, Denmark
21 shared publications - Emily Armbruster
CUNY Advanced Science Research Center 2 Structural Biology Initiative City University of New York, New York, New York
21 shared publications - Harsh Bansia
New York University
21 shared publications - Isabelle Theret
Servier Laboratories, Servier Research Institute, Gif-sur-Yvette, France
21 shared publications - Janus Schou Jakobsen
Servier Symphogen A/S 1 , Ballerup, Denmark
21 shared publications
Latest Publications
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti–PD-1 Therapy
Table S9: Alanine mutation epitope mapping for Sym024, aa positions
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti–PD-1 Therapy
Table S9: Alanine mutation epitope mapping for Sym024, aa positions
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti–PD-1 Therapy
Table S4: Parameters and statistics for cryo-EM data
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti–PD-1 Therapy
Table S4: Parameters and statistics for cryo-EM data
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti–PD-1 Therapy
Figure S9: TGI studies, mouse MC38 and CT26 tumor models
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti–PD-1 Therapy
Figure S9: TGI studies, mouse MC38 and CT26 tumor models
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti–PD-1 Therapy
Figure S3: Inhibition of cell surface CD73
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti–PD-1 Therapy
Figure S3: Inhibition of cell surface CD73
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti–PD-1 Therapy
Figure S10: Cynomolgus pharmacokinetics of Sym024
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti–PD-1 Therapy
Figure S10: Cynomolgus pharmacokinetics of Sym024
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti–PD-1 Therapy
Table S3: Cell line CD73 protein levels and enzymatic activity
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti–PD-1 Therapy
Table S3: Cell line CD73 protein levels and enzymatic activity
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti–PD-1 Therapy
Table S7: Molecular weights, SEC-MALS data
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti–PD-1 Therapy
Table S7: Molecular weights, SEC-MALS data
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti–PD-1 Therapy
Figure S7: Intrinsic tumor effect, MDA-MB-231 vs. A375, Calu-6
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti–PD-1 Therapy
Figure S7: Intrinsic tumor effect, MDA-MB-231 vs. A375, Calu-6
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti–PD-1 Therapy
Figure S2: Sym024 binding, Cynomulgus and mouse CD73
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti–PD-1 Therapy
Figure S2: Sym024 binding, Cynomulgus and mouse CD73
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti–PD-1 Therapy
Figure S5: Additional SEC-MALS and epitope mapping
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti–PD-1 Therapy
Figure S5: Additional SEC-MALS and epitope mapping